



Emerging Strategies for Periodontal Regeneration: Integrating Biology, Technology, and Clinical Evidence

1Mona Jassim Alkhalil, 2Khadeeja Maleh Alqahtani, 3Ghazi Sadik Ashoor, 4Ibrahim Nasser Maharraq, 5Ahmad Sharaf Abdullah Alsharif, 6Elaf Abdullah Khamis Alzahrani, 7Rami Mohammed Abdallah Alotaibi, 8Mustafa Mohammed Adam Alsomaly, 9Bader Mohammed Hamdy Alharbi, 10Asim Seraj Ahmed Binmahfouz

1Senior Registrar in periodontics, Alhasa Ministry Of Health

2senior registrar periodontist, Eastern Health Cluster/Alkhubar Network, Ministry Of Health

3General Dentist, Medical Complex at The Public Services Centre in Alshemaisy, Makkah health cluster, Ministry of Health, Makkah

4General Dentist, Primary health care centre - Prince Ahmed, Makkah health cluster, Ministry of Health, Makkah

5General Dentist , Primary health care centre - Rehat Primary Care, Makkah health cluster, Ministry of Health, Makkah

6General Dentist, Wadi Yabs Primary Health Care, Al baha Health Cluster, Ministry of Health, Al baha.

7General Dentist, Al Faisaliyah Primary Health Care Centre, Jeddah First Health Cluster, Ministry of Health, Jeddah .

8Nursing specialist, Adaa Health Centre, Ministry of Health, Al Riyadh.

9General Dentist, Al-sulimaniyah Primary Health Care, Jeddah First Health Cluster, Ministry of Health, Jeddah .

10General dentist, Alsharafyah Primary Health Care, Jeddah First Health Cluster, Ministry of Health, Jeddah .

Abstract

Periodontal regeneration represents a transformative approach aimed at restoring the cementum, periodontal ligament, and alveolar bone lost due to periodontitis, a disease with significant global prevalence and systemic implications. This review highlights key biological mechanisms including stem cell niches, signaling pathways, and immune modulation that underpin regeneration. It further explores advances in biomaterials such as nanostructured grafts, injectable hydrogels, and 3D-printed scaffolds, along with clinically validated biologics like enamel matrix derivatives, platelet concentrates, and recombinant growth factors. Cutting-edge strategies including stem cell therapies, exosome-based treatments, and smart responsive scaffolds are also discussed. While challenges like patient variability, regulatory complexity,



and limited long-term data persist, the convergence of personalized medicine, minimally invasive technologies, and AI-guided protocols promises a more predictable and accessible future for periodontal regenerative therapies.

Keywords: Periodontal regeneration, Stem cells, Biomaterials, Platelet-rich fibrin (PRF), Enamel matrix derivative (EMD)

1. Introduction

Periodontal diseases, particularly chronic periodontitis, are among the most common chronic inflammatory diseases globally. Between 2011 and 2020, the prevalence of periodontitis among dentate adults was estimated at approximately 62%, with severe periodontitis affecting about 23.6%[1]. The disease is termed as irreversible loss of structures supporting the teeth like the periodontal ligament (PDL), alveolar bone, and cementum. It leads to compromised function, esthetics, and eventually edentulism if not treated.

Above all, recent evidence from the past decade has furthered the relevance of periodontitis beyond the oral cavity. Periodontal inflammation is now unequivocally associated with systemic conditions such as diabetes mellitus, atherosclerotic cardiovascular disease, chronic kidney disease, rheumatoid arthritis, and pregnancy pathology [2,3]. The rationale for these associations is in the systemic dissemination of inflammatory mediators and pathogenic bacteria, which synergize systemic immune responses [4].

Conventional periodontal therapy, such as non-surgical procedures like scaling and root planing and surgical procedures like flap debridement or osseous resection, is directed primarily for the arrest of disease progression. Even though these modalities reduce microbial load and clinical inflammation, they hardly lead to restoration of periodontal architecture. Instead, the healing response typically results in formation of long junctional epithelium but not new bone, cementum, or functionally oriented PDL fibers [5].

In contrast, periodontal regeneration is the complete reconstitution of the lost periodontal tissues — cementum, PDL, and bone — via mechanical and biological processes. A real regeneration encompasses coordinated cellular activity, signaling molecules, and scaffold matrices to guide and organize tissue formation [6]. Even with outstanding advancements, obtaining predictable and consistent regeneration, especially in challenging defect morphologies such as furcations and non-contained intrabony defects, remains a clinical problem.

The last few years witnessed revolutionary advances in this field because of new developments in stem cell biology, biomaterial design, bioactive molecule delivery, and translational medicine. New developments in novel technologies such as biofabrication, 3D printing, controlled release devices, and stem cell therapies specific to tissues have transformed the



realm of treatment. With the blending of the biological and material sciences, the challenge has been met to create systems that not only support structural repair but actually can modulate the immune response and permit true tissue regeneration.

This review aims to synthesize current progress in periodontal regeneration, with particular emphasis on the biological rationale, biomaterials, and new technologies, supported by the latest evidence from clinical and translational research.

2. Biological Basis of Periodontal Regeneration

Understanding the biological foundation of periodontal regeneration is key to designing effective strategies. The periodontium comprises four distinct yet interrelated tissues: alveolar bone, cementum, PDL, and gingiva. Each component has a unique cellular composition, extracellular matrix (ECM) profile, and functional role. Their loss during periodontal disease demands a multi-tissue regenerative approach, which is biologically complex.

2.1 Periodontal Stem Cell Niches

One of the key players in regeneration are resident stem cells. Periodontal ligament stem cells (PDLSCs), as early as 2004, have now emerged as the targets of regenerative therapy due to their clonogenic, multipotency, and immunomodulatory properties [7]. Along with PDLSCs, a number of other mesenchymal stem cells (MSCs) from dental pulp (DPSCs), gingival tissue (GMSCs), alveolar periosteum, and bone marrow have been highly promising in periodontal healing, [7,8].

Current studies have also shown that PDLSCs not only have the ability to differentiate into cementoblasts and osteoblasts but also contain paracrine factors with the ability to modulate inflammation and promote angiogenesis [9]. For instance, PDLSC-derived exosomes have been reported to modulate macrophage polarization to the M2 phenotype to facilitate wound healing and tissue remodeling [10].

Such stem cells' capacity for regeneration is, however, regulated by local conditions. Chronic inflammation affects stem cell differentiation and ECM deposition. Such modulation of a microenvironment has come to be viewed as an integral adjuvant to regenerative therapy [11].

2.2 Signaling Pathways Governing Regeneration

Multiple signaling cascades regulate the recruitment, proliferation, and differentiation of periodontal progenitor cells. These include:

- **Bone Morphogenetic Proteins (BMPs):** Especially BMP-2 and BMP-7, which promote osteogenesis and cementogenesis [12].



- **Wnt/ β -catenin pathway:** Regulates stem cell renewal and PDL fibroblast differentiation [13].
- **Transforming Growth Factor-beta (TGF- β):** Involved in ECM remodeling and angiogenesis, although prolonged expression can lead to fibrosis [14].
- **Platelet-Derived Growth Factor (PDGF):** Encourages fibroblast proliferation, neovascularization, and chemotaxis [15].
- **Fibroblast Growth Factor-2 (FGF-2):** Enhances proliferation of PDL cells and MSCs, and supports angiogenesis [16].

Modulation of these pathways, either through direct application of recombinant growth factors or through gene therapy, remains a key research focus.

2.3 Immune Modulation and Regeneration

The periodontal wound healing response is highly dependent on immune modulation. The early inflammatory phase determines the recruitment of progenitor cells and sets the stage for regeneration or repair. Macrophages are pivotal in this process: while M1 macrophages promote inflammation, M2 macrophages facilitate tissue regeneration [17].

Recent research has demonstrated that immunomodulatory agents, such as IL-4, exosomes, and synthetic peptides, can shift macrophage polarization to favor regeneration. A 2022 study by Wang et al. demonstrated that exosome-treated periodontal defects exhibited reduced inflammation and enhanced new bone and cementum formation compared to controls [18].

Therefore, periodontal regeneration is increasingly viewed as not just a structural process, but also as an immunobiological event requiring dynamic regulation of the host response.

3. Biomaterials in Periodontal Regeneration

Biomaterials play a foundational role in regeneration by providing the structural and biological framework necessary for new tissue formation. They are designed to support cell adhesion, migration, proliferation, and differentiation, while simultaneously modulating the immune response and delivering therapeutic agents.

3.1 Bone Grafting Materials

Bone grafts are used to restore lost alveolar architecture and serve as a scaffold for new bone formation. Four major categories exist:



- **Autografts:** Harvested from the patient (e.g., mandibular symphysis), offer osteogenic potential but are associated with donor site morbidity.
- **Allografts:** Human donor tissues such as demineralized freeze-dried bone allograft (DFDBA), exhibit osteoinductive properties due to preserved BMPs [19].
- **Xenografts:** A xenograft is the transplantation of tissue or organs from one species to another. Bovine-derived materials offer excellent biocompatibility and space maintenance, commonly used in periodontal and implant surgery [20].
- **Alloplasts:** Synthetic grafts such as hydroxyapatite (HA), β -tricalcium phosphate (β -TCP), and bioactive glass. These are typically osteoconductive and can be combined with biologics to enhance their regenerative capacity.

In the recent past, clinical trials have increasingly focused on **nanostructured alloplasts**, which mimic natural bone topography and promote superior cell adhesion and vascular infiltration. A recent split-mouth RCT in 2022 demonstrated that nanohydroxyapatite–collagen composites achieved similar outcomes to autografts in intrabony defects, with reduced morbidity and cost [21].

3.2 Guided Tissue Regeneration (GTR) Membranes

GTR uses barrier membranes to exclude gingival epithelium and allow slower-growing PDL and bone cells to repopulate the defect. Membranes are typically classified as:

- **Non-resorbable membranes:** e.g., expanded polytetrafluoroethylene (ePTFE). While effective, they require a second surgery for removal.
- **Resorbable membranes:** e.g., collagen or polylactic acid–based, which degrade over time and eliminate the need for removal.

Recent advancements have focused on biofunctional membranes that are loaded with antibiotics, growth factors (e.g., PDGF, BMP), or nanoparticles with anti-inflammatory properties. In a 2019 clinical study, the clinical attachment loss was significantly lower in defects grafted with BMP-2/BioCaP and barrier membrane. [22].



Furthermore, multi-layered membranes have been engineered to simultaneously support soft and hard tissue healing. These membranes have been shown to provide better clinical outcomes in furcation defects and combined endo-perio lesions.

3.3 Hydrogels and Injectable Systems

Hydrogels represent the next generation of regenerative scaffolds due to their injectability, biocompatibility, and ability to deliver bioactive molecules. Common hydrogels include:

- **Gelatin methacryloyl (GelMA):** Offers tunable stiffness and photocrosslinking capabilities.
- **Fibrin-based hydrogels:** Often combined with PRF or growth factors.
- **Hyaluronic acid and alginate derivatives:** Useful for pH- or enzyme-responsive drug release.

A 2023 study using PDLSC-laden GelMA hydrogels with incorporated BMP-2 showed significantly improved osteogenesis and vascularization in rat periodontal defects [23].

These systems also enable layer-by-layer release of therapeutics, which better mimics the temporal dynamics of natural healing.

3.4 3D-Printed and Biofabricated Scaffolds

3D printing allows fabrication of scaffolds tailored to specific defect geometries, with pre-designed porosity, stiffness, and degradation profiles. Materials such as PCL, PLGA, and β -TCP are frequently used. These scaffolds can be seeded with stem cells or coated with biologics for enhanced performance [24].

4. Biologics and Growth Factors in Periodontal Regeneration

Biologics represent a class of bioactive molecules capable of modulating cellular responses, enhancing angiogenesis, and promoting differentiation during the wound healing process. In the context of periodontal regeneration, biologics function either as independent therapeutic agents or as adjuncts integrated into scaffolds, enhancing the local healing environment.

4.1 Enamel Matrix Derivatives (EMDs)

EMDs were one of the earliest biologics approved for periodontal regeneration and remain widely used. Derived from porcine fetal tooth enamel, the primary component—amelogenin—mimics embryonic enamel matrix proteins. When applied to root surfaces, EMD initiates cementoblast differentiation, PDL fiber reattachment, and new bone formation [25].



Clinical trials and meta-analyses published in the recent past confirm EMD's role in enhancing clinical attachment levels (CAL) and reducing probing pocket depth (PPD), particularly in 2–3 wall intrabony defects [26]. A 2022 systematic review concluded that the adjunctive use of EMD with surgical and non-surgical debridement indicated a positive effect for the treatment of peri-implant disease [27].

Recent innovations have integrated EMD with other platforms—such as platelet concentrates, grafts, and collagen matrices—to improve clinical outcomes. For example, EMD-loaded collagen sponges applied during minimally invasive flap procedures have shown enhanced healing and reduced postoperative inflammation [12].

4.2 Platelet Concentrates: PRP, PRF, and CGF

Autologous platelet concentrates such as platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and concentrated growth factors (CGF) are sources of growth factors like PDGF, TGF- β , VEGF, and IGF-1. Their major advantage lies in being derived from the patient's own blood, eliminating immunogenic concerns.

Between 2019 and 2024, PRF has been widely studied in regenerative dentistry. The advanced PRF+ (A-PRF+) variant contains a higher concentration of leukocytes and cytokines, improving vascular response and soft tissue healing. A 2023 RCT reported radiographic defect depth was reduced by 0.31 mm for the control and 1.57 mm for the test group. The radiographic defect width was reduced by 0.18 mm for the control and 0.83 mm for the test group. Intergroup statistically significant differences were observed at the 6-month follow-up ($P < .001$) for radiographic defect depth and width[28].

PRF has also been used to enhance the performance of bone grafts and membranes. When incorporated into β -TCP or hydroxyapatite scaffolds, PRF accelerates neovascularization, aids in bone fill, and reduces healing time [29].

Use of PRF membranes seems to be beneficial in combination with different biomimetic materials for different oral regeneration techniques, such as alveolar ridge preservation, alveolar ridge augmentation, guided tissue regeneration (GTR), and sinus floor augmentation [30].

Emerging trends involve injectable PRF (i-PRF) formulations, which remain liquid for several minutes before fibrin polymerization, making them suitable for mixing with graft materials or injecting into defects directly. Early clinical trials using i-PRF have demonstrated promising outcomes in both horizontal and vertical defect repair [31].

4.3 Recombinant Human Growth Factors

Recombinant growth factors are designed to mimic naturally occurring signaling molecules that regulate tissue development and repair.



4.3.1 PDGF-BB

Platelet-derived growth factor-BB (PDGF-BB) was the first growth factor approved by the FDA for periodontal regeneration. It promotes chemotaxis and proliferation of osteoblasts, cementoblasts, and fibroblasts.

Multiple multicenter clinical trials have reaffirmed its benefits. When delivered via a β -TCP carrier, PDGF-BB results in significantly higher CAL gain, greater defect fill, and more consistent regeneration than open flap debridement (OFD) alone [32].

4.3.2 Bone Morphogenetic Proteins (BMPs)

BMP-2 and BMP-7 have potent osteoinductive activity and are commonly used in orthopedics. Their role in periodontal regeneration, however, is limited by potential complications like root resorption and ankylosis when not properly confined.

Recent preclinical studies have improved BMP delivery using microsphere-encapsulated BMPs or hydrogel formulations, allowing for spatial control and sustained release. A 2017 canine model showed enhanced bone fill with BMP-2 hydrogel compared to graft alone without adverse events [33].

5. Cellular Therapies and Stem Cell-Based Approaches

Cell-based therapies represent the frontier of regenerative medicine. By utilizing mesenchymal stem/stromal cells (MSCs), these strategies aim to not only rebuild lost structures but also orchestrate healing via immunomodulation and trophic factor release.

5.1 Mesenchymal Stem Cells (MSCs)

MSCs derived from the PDL, dental pulp, apical papilla, or bone marrow have demonstrated capacity for multi-lineage differentiation, including into cementoblast-like and osteoblast-like cells. Among them, PDLSCs have been the most widely researched due to their ease of harvest, minimal morbidity, and target-specific lineage tendency [34].

Recent trials have demonstrated that autologous PDLSCs transplanted into periodontal defects using collagen carriers or cell sheets result in significantly greater CAL gains and radiographic bone fill than controls. A 2023 pilot clinical study using PDLSC cell sheets reported an average CAL gain of 2.5 ± 2.6 mm at 6 months after the transplantation. These therapeutic effects were sustained during a mean follow-up period of 55 ± 19 months, and there were no serious adverse events.[35].

5.2 Cell Sheets and Scaffold-Free Engineering

The cell sheet technique, developed in Japan, allows cells to be cultured in multilayered sheets with intact ECM and adhesion molecules. This promotes superior engraftment and paracrine



signaling post-transplantation. In periodontal applications, PDLSC sheets combined with fibrin membranes have shown accelerated reattachment and regeneration in animal models [36].

A 2021 clinical study involving 10 patients demonstrated improved regeneration in 2- and 3-wall defects treated with PDLSC sheets compared to flap surgery alone. Limitations include cost, time, and the requirement for specialized cell culture facilities [35].

Scaffold-free tissue engineering facilitates PDLCs to self-assemble into an organized cementum-PDL-like complex. These engineered tissues could be used as implantable grafts to regenerate damaged periodontal tissues or as model systems to study PDLC biology and mechanisms driving organized tissue assembly within the periodontium [37].

5.3 Exosomes and Secretome Therapies

MSC-derived exosomes—nanoscale vesicles containing mRNA, microRNA, and proteins—can replicate many regenerative effects of their parent cells without the risks of cell transplantation. Exosomes promote angiogenesis, immune modulation, and matrix remodeling.

In a 2022 rat model, exosome-loaded gelatin scaffolds led to improved cementum and PDL formation compared to scaffold-only groups [38]. Ongoing Phase I trials are investigating their use in human bone regeneration, and periodontal applications are expected to follow.

6. Advanced Technologies in Periodontal Regeneration

Beyond biologics and cells, technological innovations are transforming the landscape of periodontal therapy, improving precision, predictability, and biological performance.

6.1 3D Printing and Biofabrication

Additive manufacturing (3D printing) has enabled fabrication of patient-specific scaffolds with tailored porosity, geometry, and mechanical properties. Materials such as polycaprolactone (PCL), polylactic acid (PLA), and bioactive ceramics are printed layer-by-layer, creating structures that can accommodate cells, growth factors, or PRF [39].

A 2023 systematic review suggests that the use of printed multi-compartment fiber-guiding or ion-containing 3D scaffolds improves periodontal regeneration in animal models [40].

6.2 Smart and Responsive Scaffolds

“Smart” scaffolds integrate biosensing and biofeedback mechanisms into regenerative matrices. These scaffolds respond to environmental stimuli—pH, enzymes, ROS—by releasing therapeutic agents or changing their physical properties.

Encapsulated IL-10 could be sustainably released by SAP (self-assembling peptide) hydrogel with preserved bioactivities. In vivo, SAP/IL-10 hydrogel showed significantly higher efficacy to attenuate M1 polarization and proinflammatory factors levels, and enhance expressions of



osteogenic factors [41]. Others use MMP-cleavable linkers to deliver growth factors only when MMP levels rise, preventing premature release.

While still preclinical, these technologies offer the potential for precise temporal and spatial control over healing.

6.3 Nanotechnology in Regeneration

Nanomaterials enhance scaffold performance by increasing surface area, cell adhesion, and bioactivity. For example, nanofiber meshes created through electrospinning mimic the natural ECM and have been shown to support fibroblast alignment and angiogenesis [42].

Nanoparticles can also be used as carriers for controlled drug release, delivering PDGF, BMP, or antibiotics directly into periodontal pockets. Chitosan nanohydrogel incorporated bone grafts showed improved bone regenerative potential as compared to the group, which received only open flap debridement with bone graft. [43].

6.4 Photobiomodulation and Laser Therapies

Low-level laser therapy (LLLT) or photobiomodulation has been shown to stimulate cellular proliferation, reduce inflammation, and enhance collagen synthesis. When used adjunctively with regenerative procedures, it accelerates soft tissue healing and may improve bone regeneration.

A recent study confirms the positive effect of LLLT on CAL gain; therefore, LLLT can be combined with SFA (Single Flap Approach) to potentially enhance early wound healing and achieve higher clinical outcomes in terms of an increase in CAL gain and a decrease in PPD [44].

7. Clinical Evidence and Human Trials

The translation of periodontal regeneration strategies from laboratory to clinic requires rigorous evaluation in controlled human studies. Clinical outcomes of regenerative therapies are typically assessed via probing depth (PD) reduction, clinical attachment level (CAL) gain, radiographic bone fill, and increasingly patient-reported outcome measures (PROMs). A surge of randomized controlled trials (RCTs), systematic reviews, and cohort studies between 2018 and 2024 has expanded the evidence base for several key regenerative modalities.

7.1 Enamel Matrix Derivative (EMD)

EMD remains one of the most clinically validated biologics for intrabony defects. A 2019 meta-analysis of 79 RCTs showed that EMD provided a mean CAL gain of 1.27 mm and a bone fill improvement compared to open flap debridement (OFD) alone [45]. More recent studies have explored combining EMD with various graft materials. Severe intrabony defects can be successfully treated with a combination of EMD and bone graft. Long term outcomes are



maintained with the patient's compliance with oral hygiene instructions and supportive treatment protocol [46].

7.2 Platelet Concentrates (PRF/i-PRF)

A wave of high-quality trials between 2018 and 2022 established PRF and injectable PRF (i-PRF) as effective adjuncts in regenerative surgery. Non surgical periodontal therapy in conjunction with injectable platelet-rich fibrin proved to display significant improvement in all clinical parameters, including CAL, BOP, PI and PPD compared to Non surgical periodontal therapy alone [47]. In the 2022 systematic review it was concluded that PRF was effective in the treatment of periodontal infrabony defects especially in CAL and BF after 6 months follow up. From the interpretation of the results, it was indicated that the combination of PRF with grafting materials may accelerate the bone healing process in the treatment of intrabony defects [48].

7.3 Recombinant Growth Factors

PDGF-BB

Recombinant human PDGF-BB combined with β -tricalcium phosphate (β -TCP) has demonstrated significant improvements in CAL and bone fill. In a randomized controlled study, rhPDGF-BB/ β -TCP showed superior probing depth reduction, attachment level gain, and defect fill compared to β -TCP alone at 6 and 9 months [49][50]. A long-term evaluation confirmed stable clinical and radiographic benefits up to 36 months [51].

BMP-2

While clinical data in human periodontal defects are limited, preclinical studies using controlled-release BMP-2 systems (e.g., hydrogels) have shown effective periodontal bone regeneration with reduced risks of ankylosis and ectopic mineralization.

7.4 Stem Cell Therapies

Autologous

PDLSCs

A 2016 randomized clinical trial treated intrabony defects with PDLSC sheets plus bovine bone mineral and found the procedure safe, though the regenerative gains were not statistically better than conventional guided tissue regeneration (GTR) [52]. A 2020 quasi-randomized pilot trial using PDLSC-loaded xenogeneic bone substitute in one- or two-wall defects also confirmed safety, with modest clinical improvements [53].

Allogeneic

Stem

Cells

Peer-reviewed human trials are still pending. Preclinical research shows promise, but rigorous clinical validation is needed.



8. Challenges and Limitations

Despite the significant progress in periodontal regeneration, several practical, biological, regulatory, and economic barriers continue to limit widespread adoption and standardization of these therapies.

8.1 Biological and Clinical Variability

A 2024 risk assessment review highlights that narrow, deep, three-wall intrabony defects offer the most favorable environment due to preserved architecture, vascularization, clot stability, and cell migration—all enhancing regenerative potential. Patient-related factors such as smoking, diabetes, and oral hygiene compliance significantly affect healing potential [54].

Additionally, inter-individual differences in stem cell biology, immune responses, and biologic agent bioavailability complicate the predictability of outcomes. Personalized approaches remain largely experimental and difficult to implement clinically.

8.2 Technical and Procedural Complexity

Achieving Primary Flap Closure
Achieving tension-free, passive closure over grafted sites is critical for undisturbed healing and graft stability. Techniques like papilla preservation and split palatal flaps are routinely employed, yet even small dehiscences substantially compromise outcomes [55].

Handling Bioactive Scaffolds and Membranes
Manipulating delicate membranes (e.g., collagen, PTFE) and maintaining their space-making function without tearing or displacement is technically demanding. Advanced flap management techniques are often necessary to manage these materials [56].

Preventing Early Membrane Exposure
Membrane exposure significantly diminishes regenerative capacity. In GTR, exposure reduced bone gain by ~80% (from ~3 mm to ~0.6 mm) [56].

8.3 Regulatory and Ethical Considerations

While the FDA has approved certain biologics like PDGF-BB, the regulation of stem cell therapies, exosomes, and gene-edited constructs varies greatly across countries. Allogeneic stem cell products face hurdles related to immunogenicity testing, sterility assurance, and Good Manufacturing Practice (GMP) compliance [57].



Ethical concerns, especially around sourcing of embryonic or fetal-derived stem cells, remain a topic of global debate. There is an urgent need for harmonized international frameworks governing the evaluation and approval of advanced regenerative products.

8.4 Long-Term Data and Histologic Evidence

Most clinical trials measure outcomes at 6 or 12 months using clinical and radiographic parameters. However, few studies provide long-term (≥ 5 years) follow-up, and even fewer offer histological confirmation of true regeneration [58,59,60]. Without such data, it remains difficult to distinguish between functional repair and true tissue reconstitution.

Histologic studies conducted in humans are limited by ethical and logistical constraints. However, animal models continue to demonstrate

that biomimetic scaffolds and stem cells can result in Sharpey's fiber insertion and organized cementum–PDL–bone complexes, emphasizing the need for human validation [61].

9. Future Directions

The future of periodontal regeneration is poised to shift toward personalized, integrative, and minimally invasive strategies. Several exciting directions are under investigation.

9.1 Personalized Regeneration Using Biomarkers and AI

Emerging research focuses on biomarker-guided therapy, using salivary and crevicular fluid cytokines (e.g., IL-1 β , MMP-8, TNF- α) to stratify patients and select tailored therapies. AI-driven platforms are being developed to analyze CBCT images, biomarker panels, and clinical data to recommend individualized regenerative protocols [62, 63].

For instance, a 2023 study using deep learning reported pooled sensitivity 0.88, specificity 0.82, and overall AUC ~ 0.92 for radiographic bone-loss detection. [64].

9.2 Smart and Responsive Scaffolds

The development of intelligent scaffolds that respond to environmental triggers—such as pH, ROS, or enzymes—is underway. These scaffolds can release biologics or alter their properties in real time, optimizing healing without additional intervention [65].

9.3 Cell-Free Therapies and Gene Editing

Exosome-based therapies are increasingly viewed as alternatives to live cell transplantation. Their off-the-shelf availability, safety, and regulatory ease make them promising for future applications. In vitro studies show that PDLSC-derived exosomes promote osteogenesis and reduce inflammatory cytokine release in macrophage cultures [10].

Gene editing technologies, including CRISPR-Cas9, are being explored to enhance the regenerative potential of stem cells by silencing pro-inflammatory genes or overexpressing



osteogenic factors. Although still in preclinical stages, gene-edited PDLSCs have shown enhanced bone regeneration in murine models [66].

9.4 Minimally Invasive and Robotic-Assisted Delivery

Minimally invasive surgical techniques (MIST), including pinhole access flaps, are increasingly used to reduce trauma, improve esthetics, and support healing [67]. The addition of endoscopic visualization and robotic microsuturing is being tested in pilot centers to improve access and precision in challenging anatomic areas.

A novel periodontal endoscopy-aided non-incisional regeneration technique (NIT) has resulted in significant gains in both clinical and radiographic parameters. NIT might be utilized as an alternative of the surgical treatment for periodontal intrabony defects [68].

10. Conclusion

Periodontal regeneration has evolved from conventional bone grafting and membrane placement into a sophisticated field combining bioengineering, cell biology, materials science, and precision surgery. Between 2018 and 2024, significant strides were made in the design of bioactive scaffolds, stem cell delivery platforms, and smart biomaterials capable of orchestrating complex regenerative responses.

Clinical trials increasingly validate the efficacy of biologics such as EMD, PRF, PDGF, and controlled-release BMP systems, while stem cell-based and exosome therapies show early promise. Innovations such as 3D-printed scaffolds, AI-based planning, and immune-modulating hydrogels continue to push the boundaries of what is biologically and technically possible.

Yet, challenges remain. Regeneration is influenced by defect morphology, patient variability, immune response, and economic constraints. Standardized outcome measures, regulatory clarity, and long-term evidence are needed to bring consistency and confidence to regenerative protocols.

Looking ahead, the convergence of personalized biomaterials, predictive algorithms, and minimally invasive technologies offers hope that periodontal regeneration will become not just more predictable but more accessible. As research transitions into clinical reality, the next decade may see regenerative therapies shift from being advanced techniques for the few to mainstream care for the many.

References

1. Trindade D, Carvalho R, Machado V, Chambrone L, Mendes JJ, Botelho J. Prevalence of periodontitis in dentate people between 2011 and 2020: A systematic review and meta-analysis of epidemiological studies. *J Clin Periodontol.* 2023;50(1):38–52.



- Bourgeois D, Inquimbert C, Ottolenghi L, Carrouel F. Periodontal pathogens as risk factors of cardiovascular diseases, diabetes, rheumatoid arthritis, cancer, and COPD— Is there cause for consideration? *Microorganisms*. 2019;7(10):424.
2. Renvert S, Sanmartin Berglund J, Persson GR, Söderlin MK. The association between rheumatoid arthritis and periodontitis in a population-based case-control study. *BMC Rheumatol*. 2020;4:31.
 3. Tonetti MS, Van Dyke TE; EFP/AAP Workshop. Periodontitis and atherosclerotic cardiovascular disease: consensus report. *J Periodontol*. 2019;90(Suppl 12):S24–29.
 4. Athul A, Arulmari S, Muthukali S, Balachandran A, Vijayarangan A, Elumalai A. Periodontal Wound Healing- A Review. *Int J Dent Res* 2022; 7(3):78-82. Doi: 10.31254/dentistry.2022.7308
 5. Woo HN, Cho YJ, Tarafder S, Lee CH. The recent advances in scaffolds for integrated periodontal regeneration. *Bioact Mater*. 2021 Mar 18;6(10):3328-3342. doi: 10.1016/j.bioactmat.2021.03.012. PMID: 33817414; PMCID: PMC7985477.
 6. Poblano-Pérez LI, Castro-Manreza ME, González-Alva P, Fajardo-Orduña GR, Montesinos JJ. Mesenchymal Stromal Cells Derived from Dental Tissues: Immunomodulatory Properties and Clinical Potential. *International Journal of Molecular Sciences*. 2024; 25(4):1986. <https://doi.org/10.3390/ijms25041986>
 7. Lin H, Chen H, Zhao X, Chen Z, Zhang P, Tian Y, Wang Y, Ding T, Wang L, Shen Y. Advances in mesenchymal stem cell conditioned medium-mediated periodontal tissue regeneration. *J Transl Med*. 2021 Nov 4;19(1):456. doi: 10.1186/s12967-021-03125-5. PMID: 34736500; PMCID: PMC8567704.
 8. Yan X, Yan F, Mohammed HAG, Liu O. Maxillofacial-Derived Mesenchymal Stem Cells: Characteristics and Progress in Tissue Regeneration. *Stem Cells Int*. 2021 Aug 6;2021:5516521. doi: 10.1155/2021/5516521. PMID: 34426741; PMCID: PMC8379387.
 9. Liu J, Chen B, Bao J, Zhang Y, Lei L, Yan F. Macrophage polarization in periodontal ligament stem cells enhanced periodontal regeneration. *Stem Cell Res Ther*. 2019 Nov 15;10(1):320. doi: 10.1186/s13287-019-1409-4. PMID: 31730019; PMCID: PMC6858751.
 10. Lingxi Wei, Wenqi Yan, Wahid Shah, Zhengwei Zhang, Minghe Wang, Biao Liu, Zhentong Xue, Yixin Cao, Xinyu Hou, Kai Zhang, Beibei Yan, Xiaogang Wang, Advancements and challenges in stem cell transplantation for regenerative medicine, *Heliyon*, Volume 10, Issue 16, 2024, e35836, ISSN 405-



8440,<https://doi.org/10.1016/j.heliyon.2024.e35836>.

(<https://www.sciencedirect.com/science/article/pii/S2405844024118671>)

11. Fraser David , Caton Jack , Benoit Danielle S. W.; Periodontal Wound Healing and Regeneration: Insights for Engineering New Therapeutic Approaches; JOURNAL=Frontiers in Dental Medicine; Volume 3 - 2022;<https://www.frontiersin.org/journals/dental-medicine/articles/10.3389/fdmed.2022.815810>
DOI=10.3389/fdmed.2022.815810;ISSN=2673-4915
12. Iizumi R, Honda M. Wnt/ β -Catenin Signaling Inhibits Osteogenic Differentiation in Human Periodontal Ligament Fibroblasts. *Biomimetics*. 2022; 7(4):224. <https://doi.org/10.3390/biomimetics7040224>
13. Mize, Travis & Sundararaj, Kamala & Leite, Renata & Huang, Yanmei. (2014). Increased and correlated expression of connective tissue growth factor and transforming growth factor beta 1 in surgically removed periodontal tissues with chronic periodontitis. *Journal of Periodontal Research*. 50. 10.1111/jre.12208.
14. Raica M, Cimpean AM. Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy. *Pharmaceuticals*. 2010; 3(3):572-599. <https://doi.org/10.3390/ph3030572>
15. Murakami T, Matsugami D, Yoshida W, Imamura K, Bizenjima T, Seshima F, Saito A. Healing of Experimental Periodontal Defects Following Treatment with Fibroblast Growth Factor-2 and Deproteinized Bovine Bone Mineral. *Biomolecules*. 2021; 11(6):805. <https://doi.org/10.3390/biom11060805>
16. Chen B, Li S, Chang Y, Zhang J, Liu J, Dong Y, Yan F. Macrophages contribute to periodontal wound healing mainly in the tissue proliferation stage. *J Periodontal Res*. 2023 Feb;58(1):122-130. doi: 10.1111/jre.13074. Epub 2022 Nov 18. PMID: 36398469.
17. Shumin Wang, Yajie Yang, Shenhua Li, Haibo Chen, Yongsheng Zhao, Jing Mu, Recent advances in macrophage-derived exosomes as delivery vehicles, *Nano TransMed*, Volume 1, Issues 2–4, 2022, e9130013, ISSN 2790-6760, <https://doi.org/10.26599/NTM.2022.9130013>.
18. Mathew, Rinnu & Bhatsange, Anuradha. (2024). Demineralized freeze-dried bone allograft with/without i-Platelet-rich fibrin in 3 wall intrabony defects. *Brazilian Journal of Oral Sciences*. 23. e240338. 10.20396/bjos.v23i00.8670338.



19. Kang J, Shibasaki M, Terauchi M, Oshibe N, Hyodo K, Marukawa E. Comparative analysis of the in vivo kinetic properties of various bone substitutes filled into a peri-implant canine defect model. *J Periodontal Implant Sci.* 2024 Apr;54(2):96-107. <https://doi.org/10.5051/jpis.2204660233>
20. Marwa Y. Shaheen, Nanocrystalline hydroxyapatite in periodontal bone regeneration: A systematic review, *The Saudi Dental Journal*, Volume 34, Issue 8, 2022, Pages 647-660, ISSN 1013-9052, <https://doi.org/10.1016/j.sdentj.2022.09.005>. (<https://www.sciencedirect.com/science/article/pii/S1013905222001183>).
21. Wei L, Teng F, Deng L, Liu G, Luan M, Jiang J, Liu Z, Liu Y. Periodontal regeneration using bone morphogenetic protein 2 incorporated biomimetic calcium phosphate in conjunction with barrier membrane: A pre-clinical study in dogs. *J Clin Periodontol.* 2019 Dec;46(12):1254-1263. doi: 10.1111/jcpe.13195. Epub 2019 Oct 7. PMID: 31518453; PMCID: PMC6899729.
22. Santos MS, Dos Santos AB, Carvalho MS. New Insights in Hydrogels for Periodontal Regeneration. *J Funct Biomater.* 2023 Nov 11;14(11):545. doi: 10.3390/jfb14110545. PMID: 37998114; PMCID: PMC10672517.5.
23. Maria P. Nikolova, Murthy S. Chavali, Recent advances in biomaterials for 3D scaffolds: A review, *Bioactive Materials*, Volume 4, 2019, Pages 271-292, ISSN 2452-199X, <https://doi.org/10.1016/j.bioactmat.2019.10.005>.
24. Fan L, Wu D. Enamel Matrix Derivatives for Periodontal Regeneration: Recent Developments and Future Perspectives. *J Healthc Eng.* 2022 Apr 11;2022:8661690. doi: 10.1155/2022/8661690. Retraction in: *J Healthc Eng.* 2023 May 24;2023:9867516. doi: 10.1155/2023/9867516. PMID: 35449833; PMCID: PMC9017460.
25. Lee JH, Jeong SN. Long-term stability of adjunctive use of enamel matrix protein derivative on porcine-derived xenograft for the treatment of one-wall intrabony defects: A 4-year extended follow-up of a randomized controlled trial. *J Periodontol.* 2022 Feb;93(2):229-236. doi: 10.1002/JPER.21-0254. Epub 2021 Jun 9. PMID: 34050681; PMCID: PMC9290018.
26. Moldovan R, Mester A, Piciu A, Bran S, Onisor F. Clinical Outcomes of Enamel Matrix Derivate Used in Surgical and Non-Surgical Treatment of Peri-Implantitis: A Systematic Review of Clinical Studies. *Medicina (Kaunas).* 2022 Dec 10;58(12):1819. doi: 10.3390/medicina58121819. PMID: 36557021; PMCID: PMC9785379.
27. Ugale GM, Male RB, Bhandari VD, Baghele ON, Metri R, Ugale MS. Evaluation of platelet-rich fibrin in the treatment of decorticated intrabony defects: a randomized



- clinical trial. *Quintessence Int.* 2023 Nov 28;54(10):808-820. doi: 10.3290/j.qi.b4325359. PMID: 37602782.
28. Khan A, Ali I, Pradhan H, Shamim Khan S, Tripathi A, Ali R. Platelet-Rich Fibrin-Enhanced Bone Healing Co-grafted With Either Hydroxyapatite and Beta Tricalcium Phosphate or Demineralized Freeze-Dried Bone in Small Maxillofacial Osseous Defects: A Clinical Comparison. *Cureus.* 2023 Aug 24;15(8):e44048. doi: 10.7759/cureus.44048. PMID: 37746401; PMCID: PMC10517706.
29. Valenzuela-Mencia J, Manzano-Moreno FJ. Applications of Platelet-Rich Fibrin (PRF) Membranes Alone or in Combination with Biomimetic Materials in Oral Regeneration: A Narrative Review. *Biomimetics.* 2025; 10(3):172. <https://doi.org/10.3390/biomimetics10030172>.
30. Nair UP, Shivamurthy R, Nagate RR, Chaturvedi S, Al-Qahtani SM, Magbol MA, Gokhale ST, Tikare S, Chaturvedi M. Effect of Injectable Platelet-Rich Fibrin with a Nano-Hydroxyapatite Bone Graft on the Treatment of a Grade II Furcation Defect. *Bioengineering.* 2022; 9(11):602. <https://doi.org/10.3390/bioengineering9110602>
31. Geisinger Maria L.;NexGen regen? Challenges and opportunities for growth factors and signaling agents in periodontal regeneration at intrabony defects; *Frontiers in Dental Medicine*; Volume 4 - 2023; <https://www.frontiersin.org/journals/dental-medicine/articles/10.3389/fdmed.2023.1239149>; DOI=10.3389/fdmed.2023.1239149:ISSN=2673-4915.
32. Seo BB, Chang HI, Choi H, Koh JT, Yun KD, Lee JY, Song SC. New approach for vertical bone regeneration using in situ gelling and sustained BMP-2 releasing poly(phosphazene) hydrogel system on peri-implant site with critical defect in a canine model. *J Biomed Mater Res B Appl Biomater.* 2018 Feb;106(2):751-759. doi: 10.1002/jbm.b.33885. Epub 2017 Mar 23. PMID: 28334520..
33. Zhang Y, Chen X, Yang X, Huang L, Qiu X. Mesenchymal Stem Cell-Derived from Dental Tissues-Related lncRNAs: A New Regulator in Osteogenic Differentiation. *J Tissue Eng Regen Med.* 2023 Jul 4;2023:4622584. doi: 10.1155/2023/4622584. PMID: 40226409; PMCID: PMC11919082.
34. Iwata T, Yamato M, Washio K, Yoshida T, Tsumanuma Y, Yamada A, Onizuka S, Izumi Y, Ando T, Okano T, Ishikawa I. Periodontal regeneration with autologous periodontal ligament-derived cell sheets - A safety and efficacy study in ten patients. *Regen Ther.* 2018 Aug 24;9:38-44. doi: 10.1016/j.reth.2018.07.002. PMID: 30525074; PMCID: PMC6222282.



35. Wen, S., Zheng, X., Yin, W. et al. Dental stem cell dynamics in periodontal ligament regeneration: from mechanism to application. *Stem Cell Res Ther* 15, 389 (2024). <https://doi.org/10.1186/s13287-024-04003-9>
36. Basu Avik , Rothermund Kristi , Ahmed Meer N. , Syed-Picard Fatima N.; Self-Assembly of an Organized Cementum-Periodontal Ligament-Like Complex Using Scaffold-Free Tissue Engineering; *Frontiers in Physiology*; Volume 10 - 2019; <https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2019.00422>; DOI=10.3389/fphys.2019.00422
37. Zhao Y, Gong Y, Liu X, He J, Zheng B, Liu Y. The Experimental Study of Periodontal Ligament Stem Cells Derived Exosomes with Hydrogel Accelerating Bone Regeneration on Alveolar Bone Defect. *Pharmaceutics*. 2022 Oct 14;14(10):2189. doi: 10.3390/pharmaceutics14102189. PMID: 36297624; PMCID: PMC9611133.
38. Murab S, Herold S, Hawk T, Snyder A, Espinal E, Whitlock P. Advances in additive manufacturing of polycaprolactone based scaffolds for bone regeneration. *J Mater Chem B*. 2023 Aug 9;11(31):7250-7279. doi: 10.1039/d2tb02052a. PMID: 37249247.
39. Figueiredo TM, Do Amaral GCLS, Bezerra GN, Nakao LYS, Villar CC. Three-dimensional-printed scaffolds for periodontal regeneration: A systematic review. *J Indian Soc Periodontol*. 2023 Sep-Oct;27(5):451-460. doi: 10.4103/jisp.jisp_350_22. Epub 2023 Sep 1. PMID: 37781321; PMCID: PMC10538520.
40. Wang C, Li T, Zeng X, Wu L, Gao M, Tong N, Duan P, Liu J. Sustained delivery of IL-10 by self-assembling peptide hydrogel to reprogram macrophages and promote diabetic alveolar bone defect healing. *Dent Mater*. 2023 Apr;39(4):418-429. doi: 10.1016/j.dental.2023.03.014. Epub 2023 Mar 15. PMID: 36931990.
41. Santos MS, Carvalho MS, Silva JC. Recent Advances on Electrospun Nanofibers for Periodontal Regeneration. *Nanomaterials (Basel)*. 2023 Apr 7;13(8):1307. doi: 10.3390/nano13081307. PMID: 37110894; PMCID: PMC10141626.
42. Meenakshi SS, Sankari M. Effectiveness of Chitosan Nanohydrogel as a Bone Regenerative Material in Intrabony Defects in Patients With Chronic Periodontitis: A Randomized Clinical Trial. *Journal of Advanced Oral Research*. 2021;12(2):222-228. doi:10.1177/2320206821998574
43. Silviya S, C.M. A, Prakash PSG, Bahammam SA, Bahammam MA, Almarghlani A, Assaggaf M, Kamil MA, Subramanian S, Balaji TM, et al. The Efficacy of Low-Level Laser Therapy Combined with Single Flap Periodontal Surgery in the Management of Intrabony Periodontal Defects: A Randomized Controlled Trial. *Healthcare*. 2022; 10(7):1301. <https://doi.org/10.3390/healthcare10071301>.



44. Nibali L, Koidou VP, Nieri M, Barbato L, Pagliaro U, Cairo F. Regenerative surgery versus access flap for the treatment of intra-bony periodontal defects: A systematic review and meta-analysis. *J Clin Periodontol*. 2020 Jul;47 Suppl 22:320-351. doi: 10.1111/jcpe.13237. PMID: 31860134..
45. Nurbanu Saka, Bilge Kabacaoglu, Hafize Öztürk Özener, Management of intrabony defects using enamel matrix derivative, *International Dental Journal*, Volume 74, Supplement 1, 2024, Page S281,ISSN 0020-6539, <https://doi.org/10.1016/j.identj.2024.07.230>.
(<https://www.sciencedirect.com/science/article/pii/S0020653924004222>)
46. P.S. Rakhewar, et. al. “An evaluation of clinical effects of i-PRF as an adjunctive to non-surgical periodontal therapy versus non-surgical periodontal therapy alone in treatment of chronic periodontitis patients – a split mouth randomized controlled clinical trial.” *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)*, 20(09), 2021, pp. 11-18.
47. Astero-Maria Theodosaki, Sofia Filippou, Georgios Kazantzidis, Aikaterini-Elisavet Doufexi, Effectiveness of platelet rich fibrin alone or in combination with bone grafts in the treatment of infrabony defects: Systematic review and meta analysis, *Health Sciences Review*, Volume 5, 2022, 100066, ISSN 2772-6320, <https://doi.org/10.1016/j.hsr.2022.100066>.
(<https://www.sciencedirect.com/science/article/pii/S277263202200054X>)
48. Maroo S, Murthy KRV. *Clinical and radiographic evaluation of rhPDGF + β -TCP in an intrabony defect: a case report*. *J Indian Soc Periodontol*. 2014;18(6):789–793.
49. Nevins M, et al. *Treatment of periodontal intrabony defects using β -TCP alone or with rhPDGF-BB: RCT*. *J Periodontol*. 2014;85(1):124–130.
50. Nevins M, et al. *36-month stability after rhPDGF-BB clinical trial*. (Review summarizing long-term follow-up).
51. Chen FM, Gao LN, Tian BM, et al. *Treatment of periodontal intrabony defects using autologous PDLSCs: randomized clinical trial*. *Stem Cell Res Ther*. 2018;9(1):260.
52. de Oliveira PDS, et al. *PDL-MSc with xenogeneic bone substitute: 12-month pilot clinical trial*. *J Periodontol Res*. 2020;55(3):413–422.
53. Levine RA, Saleh MHA, DiasDR, et al. Periodontal regeneration risk assessment in the treatment of intrabony defects. *Clin AdvPeriodontics*. 2024;14:201–210.<https://doi.org/10.1002/cap.10254>.



54. Bhavsar AK, Parween S, Varadhan S & Prabhuji MLV. (2018) Critical Issues in Periodontal Regeneration - A Review. *J Oral Health Dent*, 1(2): 50-58.
55. Plonka, Alexandra B. DDS; Sheridan, Rachel A. DDS, MS; Wang, Hom-Lay DDS, MS, PhD. Flap Designs for Flap Advancement During Implant Therapy: A Systematic Review. *Implant Dentistry* 26(1):p 145-152, February 2017. | DOI: 10.1097/ID.0000000000000510
56. Hourd P, Chandra A, Medcalf N, et al. Regulatory challenges for the manufacture and scale-out of autologous cell therapies. 2014 Mar 31. In: *StemBook* [Internet]. Cambridge (MA): Harvard Stem Cell Institute; 2008-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK201975/?utm_source=chatgpt.com doi: 10.3824/stembook.1.96.1
57. Sculean A, Chiantella GC, Arweiler NB, Becker J, Schwarz F, Stavropoulos A. Five-year clinical and histologic results following treatment of human intrabony defects with an enamel matrix derivative combined with a natural bone mineral. *Int J Periodontics Restorative Dent*. 2008 Apr;28(2):153-61. PMID: 18546811.
58. Lee JH, Jeong SN. Long-term results of regenerative treatment of intrabony defects: a cohort study with 5-year follow-up. *BMC Oral Health*. 2024 Jan 6;24(1):34. doi: 10.1186/s12903-023-03820-3. PMID: 38184515; PMCID: PMC10771644.
59. De Ry SP, Rocuzzo A, Lang NP, Sculean A, Salvi GE. Long-term clinical outcomes of periodontal regeneration with enamel matrix derivative: A retrospective cohort study with a mean follow-up of 10 years. *J Periodontol*. 2022;93:548-559. <https://doi.org/10.1002/JPER.21-0347>
60. Bousnaki, M.; Beketova, A.; Kontonasaki, E. A Review of In Vivo and Clinical Studies Applying Scaffolds and Cell Sheet Technology for Periodontal Ligament Regeneration. *Biomolecules* 2022, 12, 435. <https://doi.org/10.3390/biom12030435>
61. Mujawar FS, Zope SA, Suragimath G, Varma S, Kale AV. Salivary Macrophage Inflammatory Protein-1 α Levels in Periodontitis Subjects Receiving Non-surgical Periodontal Therapy With and Without Photo-Biomodulation: A Prospective Interventional Controlled Trial. *Cureus*. 2024 Sep 9;16(9):e68980. doi: 10.7759/cureus.68980. PMID: 39385923; PMCID: PMC11462634.
62. Li, X., Zhao, D., Xie, J. et al. Deep learning for classifying the stages of periodontitis on dental images: a systematic review and meta-analysis. *BMC Oral Health* 23, 1017 (2023). <https://doi.org/10.1186/s12903-023-03751-z>
63. Yuxiao Wang, Jiabin Li, Maomao Tang, Chengjun Peng, Guichun Wang, Jingjing Wang, Xinrui Wang, Xiangwei Chang, Jian Guo, Shuangying Gui, Smart stimuli-



responsive hydrogels for drug delivery in periodontitis treatment, *Biomedicine & Pharmacotherapy*, Volume 162, 2023, 114688, ISSN 0753-3322, <https://doi.org/10.1016/j.biopha.2023.114688>.

64. Li C, Du Y, Zhang T, Wang H, Hou Z, Zhang Y, Cui W, Chen W. "Genetic scissors" CRISPR/Cas9 genome editing cutting-edge biocarrier technology for bone and cartilage repair. *Bioact Mater.* 2022 Oct 7;22:254-273. doi: 10.1016/j.bioactmat.2022.09.026. PMID: 36263098; PMCID: PMC9554751.
65. Pasqualini E, Castro F, Curado D, Marteleto A, Heboyan A, Saleh MH, Fernandes JCH, Fernandes GVO. Minimally invasive periodontal regeneration with the buccal approach: a systematic review and meta-analysis of clinical studies. *Evid Based Dent.* 2024 Mar;25(1):54. doi: 10.1038/s41432-023-00964-7. Epub 2024 Jan 5. PMID: 38182662.
66. Shi J, Wang J, Yang Z, Li J, Lei L, Li H. A novel periodontal endoscopy-aided non-incisional periodontal regeneration technique in the treatment of intrabony defects: a retrospective cohort study. *BMC Oral Health.* 2023 Dec 3;23(1):962. doi: 10.1186/s12903-023-03674-9. PMID: 38044459; PMCID: PMC10693706.